Actively Recruiting
Study of CM559 in Healthy Subjects
Led by Keymed Biosciences Co.Ltd · Updated on 2025-09-29
40
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single center, randomized, double-blind, placebo-controlled, single dose, dose escalation Phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM559 administered intravenously at different doses in healthy male subjects.
CONDITIONS
Official Title
Study of CM559 in Healthy Subjects
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 60 years
- Voluntarily signed informed consent and able to follow study rules
You will not qualify if you...
- Smoking more than 5 cigarettes per day in the last 3 months
- Heavy alcohol use in the last 3 months, inability to avoid alcohol during study, or positive alcohol breath test
- History of drug abuse within 1 year or positive urine drug screening
- Blood loss over 400 mL or blood transfusion within 12 weeks before screening
- Suspected allergy to Ab2-antibody drugs, humanized monoclonal antibodies, biological agents, or history of severe drug allergy
- Severe trauma or major surgery within 3 months before screening, or planned surgery during study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Actively Recruiting
Research Team
Q
Qian Jia
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here